Study for the Assessment of USEG Software.
Pilot Study for the Assessment of the Quality of Echocardiography Exam When Obtained by Novice Users While Using the USEG Software.
1 other identifier
observational
99
1 country
1
Brief Summary
The product is comprised of software that aids in automated guided ultrasound image acquisition for novice users (medical professional without experience in performing echocardiography, e.g. nurses, physicians assistants, medical doctors, medical student etc.). The software provides real-time feedback during image acquisition to optimize image capture and determine whether image quality is sufficient for medical evaluation. The software is designed to be used with any echocardiographic ultrasound system. The Philips Lumify hand-held ultrasound device will be used for this study.
- Images can be acquired manually by a novice user.
- Each novice user will have a training course of 8 hours, before the study commences.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 23, 2021
CompletedFirst Posted
Study publicly available on registry
October 5, 2021
CompletedStudy Start
First participant enrolled
December 24, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 23, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 23, 2022
CompletedApril 11, 2022
February 1, 2022
1 month
September 23, 2021
April 3, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
To assess the quality of clips obtained by novice users when using the USEG software.
The expert cardiologists will evaluate whether the echo examination has sufficient to evaluate each of the primary endpoints: 1. Sufficient quality to assess Left Ventricular (LV) size: (YES/NO) 2. Sufficient quality to assess LV function: (Yes/No) 3. Sufficient quality to assess Right Ventricular size: (Yes/No) 4. Sufficient quality to assess presence of non-trivial pericardial effusion: (Yes/No)
1 year.
Secondary Outcomes (2)
Sufficient quality assessment for six (6) anatomic elements.
1 year.
Diagnostic quality assessment.
1 year.
Other Outcomes (1)
Safety outcome.
1 year.
Eligibility Criteria
Up to 100 male and female adults confirmed as eligible according to eligibility criteria.
You may qualify if:
- Age 18 and older
- Subjects willing and able to give written informed consent.
You may not qualify if:
- Emergency (non-elective) admission within 24 h prior to participating in the study
- Female subjects who are pregnant (WOCBP\* will perform a urine pregnancy test)
- Unable to lie as required in all the classic positions for standard TTE exam: supine on back / left decubitus.
- Subjects who currently participate a clinical trial, involving interventional cardiac devices
- Subjects who have prior Echo exam with description of Low/Poor quality exam in the echo report
- Subjects with BMI above 40
- Subjects experiencing a known or suspected acute cardiac event
- Subjects with severe chest wall deformity as per previous medical records and physical examination
- Subjects who have undergone pneumonectomy
- Subjects whose anatomy does not lend itself to yield diagnosable echocardiography clips (i.e. situs inversus with dextrocardia, single ventricle anatomy due to congenital heart defect, etc.)
- A woman is of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis.)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UltraSightlead
Study Sites (1)
Sheba MC
Ramat Gan, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Robert Klempfner, MD
Sheba MC
- STUDY DIRECTOR
Danny Spiegelstein, MD
UltraSight
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 23, 2021
First Posted
October 5, 2021
Study Start
December 24, 2021
Primary Completion
January 23, 2022
Study Completion
January 23, 2022
Last Updated
April 11, 2022
Record last verified: 2022-02
Data Sharing
- IPD Sharing
- Will not share